2025.08.01 09:00
간염은 간에 염증이 생긴 상태를 말한다. 급성과 만성으로 나뉘며, 방치하면 간경변증이나 간암으로 악화된다. 원인은 다양하지만 가장 흔한 형태는 바이러스 감염이다. A형, B형, C형, D형, E형 간염 외에도 면역저하자에서 발생하는 HSV, EBV, CMV 간염 등이 있다.이효영 한양대학교병원 소화기내과 교수와 함께 간염에 대해 알아봤다.◇바이러스성 간염, 무엇이 다를까A형 간염은 오염된 음식이나 물을 통해 감염되며 대부분 자연 회복된다. 하지만 성인 감염 시 증상이 심할 수 있고, 예방을 위해 백신 접종이 권장된다. B형 간염은 혈액, 체액, 출산을 통해 전염되며 국내에서 만성 간염의 가장 흔한 원인이다. 만성화되면 간암으로 이어질
2025.07.31 17:49
한양대학교 교육협력병원 센트럴병원이 건강보험심사평가원이 실시한 영상검사 적정성 평가에서 1등급을 받았다고 밝혔다.이번 평가는 방사선 피폭과 조영제 부작용 등 영상검사에 따른 환자 안전을 강화하기 위해 처음 도입됐다. 센트럴병원은 시흥·안산 지역 종합병원 중 유일하게 1등급을 획득했다.주요 평가지표는 조영제 사용 전 환자 평가, MRI 검사 전 환자 평가, 피폭 저감 프로그램 운영 등이다. 센트럴병원은 MRI 검사 전 환자 평가 항목에서 만점을 기록했다.현재 센트럴병원은 고해상도 3.0T MRI 2대, 초저선량 CT 2대를 운영하고 있으며, AI 기반 분석 시스템과 피폭 저감 프로그램도 활용 중이다. 한양대학교와 교육협력병원 협약
2025.07.31 16:54
Celltrion has published three-year clinical trial results for its Avastin biosimilar, Vegzelma (CT-P16), in the international oncology journal Cancer Treatment and Research Communications.The study presents long-term follow-up data from a global phase 3 trial evaluating the efficacy, safety, immunogenicity, and pharmacokinetics of Vegzelma in 689 patients with metastatic non-small cell lung cancer.Patients were randomized in a 1:1 ratio to receive either Vegzelma or the reference product Avastin, beginning with induction therapy every three weeks followed by maintenance monotherapy, with outco
2025.07.31 16:47
[Physician's Column] By Dong Youp Lee, Champodonamu Hospital Spine CenterStiffness or increasing pain when arching your back may be more than just muscle soreness—it could indicate spondylolysis. Spondylolysis is a stress fracture or defect in the pars interarticularis—a small segment at the rear of the vertebra—which can cause instability in spinal movement and lead to pain. Since it often resembles general lower back pain, many cases go unnoticed. However, without proper diagnosis and treatment, the condition may worsen over time.Spondylolysis commonly affects people in physically demandi
2025.07.31 16:39
SEOUL, South Korea — Cellid Co. (KOSDAQ: 299660), a South Korean biotechnology company, announced on July 29, 2025, that it has received a European patent for its proprietary adenovirus vector platform, used in its COVID-19 vaccine candidate AdCLD-CoV19-1 OMI.The patent covers an optimized vector structure designed for large-scale production of replication-incompetent adenoviruses. This achievement follows similar patent approvals in South Korea, the United States, China, Japan, and Russia, with applications still under review in Vietnam, Indonesia, Thailand, and Brazil. During the production
2025.07.31 16:36
SEOUL, South Korea — A research team led by Professors Byung-Chul Cho and Ki-Bbeum Lee, along with resident physician Ju-Seong Sim at the Yonsei Cancer Center, has identified new possibilities for MET gene-targeted therapy in solid tumor treatment, according to a study published on July 30 in Nature Reviews Clinical Oncology, a leading journal in the oncology field.The MET gene, which plays a key role in cancer cell proliferation and metastasis, has long been a primary target in the treatment of non-small cell lung cancer (NSCLC). MET overexpression in NSCLC has been associated with favorable
2025.07.31 16:33
BUSAN, South Korea — Samyook Busan Hospital announced on July 30 that it has been named one of Busan’s top institutions for international patient care in 2024 by the Busan Metropolitan City government, marking its second consecutive year receiving the honor.The recognition is part of Busan’s annual initiative to promote medical tourism, honoring 30 outstanding institutions, including general hospitals, clinics, and medical tourism agencies, based on their success in attracting foreign patients. Samyook Busan Hospital was listed among the top 10 general hospitals, alongside prominent institu
2025.07.31 16:30
SEOUL, South Korea — FirstBioTherapeutics, a biotechnology startup based in South Korea, announced on July 30 that it has been selected to join NVIDIA’s Inception program—a global initiative that supports startups leveraging artificial intelligence, data science, and high-performance computing.Through NVIDIA Inception program, selected companies gain access to GPU technologies, software development tools, technical training, and venture capital connections—aimed at accelerating innovation in frontier industries.FirstBioTherapeutics is applying AI technologies to improve the speed and accur
2025.07.31 16:28
CHICAGO — Boditech Med, a leading South Korean provider of point-of-care diagnostics, showcased a comprehensive portfolio of in-vitro diagnostic solutions at the Association for Diagnostics & Laboratory Medicine (ADLM) 2025 conference, held from July 29 to 31 in Chicago. The annual event, one of North America’s premier gatherings for laboratory medicine, attracted over 20,000 healthcare professionals and 800 companies, focusing on advancements in genomics-driven personalized diagnostics, environmental toxin detection, and artificial intelligence applications in healthcare.The company spotlig
2025.07.31 16:25
SEOUL, South Korea — Caregen, a South Korean biotech company specializing in peptide therapeutics, announced on July 30 that its weight-management peptide, Korglutide, has been officially approved as a health supplement by Indian health authorities.This regulatory milestone paves the way for Caregen to distribute and commercialize Korglutide in India, one of the world’s fastest-growing health and wellness markets. Korglutide, an oral glucagon-like peptide-1 (GLP-1) receptor agonist, offers a competitive edge over injectable GLP-1 therapies by providing user convenience and helping to preserv
2025.07.31 16:22
SEOUL, South Korea — A research team at Seoul National University Hospital has achieved a significant breakthrough in diagnosing moyamoya disease—a rare pediatric cerebrovascular disorder—by identifying a novel blood-based biomarker. The microRNA marker, miR-512-3p, shows promise as a non-invasive diagnostic tool, potentially reducing reliance on high-risk procedures such as cerebral angiography.Moyamoya disease is a progressive condition marked by narrowing of the brain’s major arteries and the formation of abnormal collateral vessels. Predominantly affecting children, it can lead to seri
2025.07.31 16:15
SEOUL, South Korea — Dencom, a South Korean medical AI company, announced on July 30 that it has signed technology and supply agreements with three U.S.-based dental IT firms—Asprodental, Casenote Software, and Velmeni. These partnerships aim to introduce Dencom’s AI-powered voice solutions to the U.S. dental market, beginning with small and mid-sized clinics and scaling to Dental Service Organizations (DSOs) and larger healthcare systems. The company has set an ambitious U.S. revenue target of $7 million by next year. Dencom’s AI solution incorporates a lightweight language model (sLLM) a
2025.07.31 16:11
SEOUL, South Korea — Chung-Ang University Hyundai Hospital announced on July 29 that it had completed a nine-day medical mission in Kazakhstan, held from July 19 to 27, delivering essential healthcare services to local communities.The mission comprised 84 volunteers, including orthopedic surgeons, general surgeons, gastroenterologists, and cardiologists from Hyundai Hospital, along with medical personnel from Mongolia’s Hyundai Hospital and local Kazakh healthcare providers. Participants also included students from Chung-Ang University’s Colleges of Medicine and Nursing, nursing students fr
주소: (07327) 서울특별시 영등포구 국제금융로2길 17 시티플라자 421호 | 전화: 02-313-2382 | 이메일: press@hinews.co.kr
제호: hinews(하이뉴스) | 등록번호: 서울,아04641 | 발행일: 2017. 8. 4
대표이사: 김국주 | 발행인: 굿닥터홀딩스 주식회사 김국주 | 편집인: 이상호 | 청소년보호책임자: 임혜정
Hinews의 모든 콘텐츠는 저작권법의 보호를 받으며 무단전재, 복사, 배포를 금합니다.
Copyright ⓒHinews. All rights reserved.
